Abstract
Immunoglobulin light-chain (AL) amyloidosis is a systemic disease characterized by the production and deposition of light chain-derived amyloid fibrils in different organs. Prompt treatment directed to the underlying plasma cell clone is crucial in order to achieve a rapid, deep and durable hematologic response. The decrease in the production of the amyloidogenic light chains is a required condition to obtain the organ response, which is commonly delayed. Meanwhile, supportive treatment is aimed to maintain quality of life of these patients and preserve their involved organs' function. From simple measures, such as salt restriction or compressive stockings, to very complex interventions, such as heart transplantation in very selected patients with isolated severe cardiac involvement, this supportive care is essential and has to be necessarily included in the multidisciplinary management of this disease.
Author supplied keywords
Cite
CITATION STYLE
Cibeira, M. T., Ortiz-Pérez, J. T., Quintana, L. F., Fernádez De Larrea, C., Tovar, N., & Bladé, J. (2020, July 1). Supportive care in AL amyloidosis. Acta Haematologica. S. Karger AG. https://doi.org/10.1159/000506760
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.